Albert-Ludwigs-Universitaet Freiburg

University of London

Cellectis

Albert-Ludwigs-Universitat Freiburg

Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Toni Cathomen

Tatjana Cornu

Jamal Alzubi

Claudio Mussolino

Gleb Sukhorukov

Irina Nazarenko

Yana Tarakanchikova

Valentina Pennucci

Marianna Romito

Philippe Duchateau

Agnes Gouble

Philipp Wolf

Giandomenico Turchiano

Georges Blattner

Gianni Monaco

Melanie Boerries

Geoffroy Andrieux

Tafadzwa Mlambo

Sandra Nitsch

Susanne Schultze-seemann

Irina Kuckuck

Antonio Carusillo

MODIFIED CAS9 SYSTEM HAVING A DOMINANT NEGATIVE EFFECTOR ON NON-HOMOLOGOUS END-JOINING FUSED THERETO AND ITS USE FOR IMPROVED GENE EDITING

The present invention relates to a novel chimeric antigen receptor (CAR) comprising an antigen-binding fragment which binds specifically to PSMA antigen, and a method of manufacturing high-quality CAR T cell products by transfection and/or transduction of T cells therewith, which allows to effectively treat tumors in vivo alone or in combination with pharmaceutical drugs, such chemotherapies, biopharmaceutical drugs, such as antibodies, or small-molecule drugs, such as protein kinase inhibitors.

Chimeric antigen receptors that bind to prostate specific membrane antigen

The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Biodegradable multilayer nanocapsules for the delivery of biologically active agents in target cells

The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.

Sequence specific reagents targeting CCR5 in primary hematopoietic cells

Disclosed is a method for high-throughput detection of genome-wide modifications in a nucleic acid genome obtained from a cell or tissue caused by the activity of a designer nuclease comprising the following steps:

Method for characterization of modifications caused by the use of designer nucleases

Herein described is a construct for epigenomic modification of genes composed of: (a) a Kr&#xfc;ppel-associated box zinc finger protein or homologous, (b) a DNA region capable of binding to the target gene or homologous, (c) a human DNA methyltransferase DNMT3A or homologous and (d) a murine DNA methyltransferase Dnmt3L or homologous, wherein components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier that can be used to silence genes coding for a protein in leukocytes that avoids the internalization of HI viruses in immune cells.

Construct for epigenetic modification and its use in the silencing of genes

Growing community of inventors

Freiburg, Germany

Toni Cathomen